Immuneering
MA - CambridgeBiotechnology
Focus: Immuneering is a Cambridge-based bioinformatics company specializing in genomics-driven oncology therapeutics. The company is in early clinical stages with a focused pipeline in solid tumors.
Profile data last refreshed 4h ago · AI intelligence enriched 2w ago
Open Jobs
5
Should You Work at Immuneering?
AI assessmentImmuneering is a speculative, early-stage bet suited for mission-driven scientists/operators comfortable with pre-clinical risk in exchange for potential upside, not established career stability.
Why Work Here
- Early-stage oncology biotech with specialized bioinformatics capability in a high-value therapeutic area
- Active hiring in Clinical Operations (4 roles) signals pipeline advancement and clinical execution focus
Data completeness
2/9 — Limited
Company HealthSolid
Pipeline
Early-stage
2 total
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
IMM-1-104 Monotherapy
Advanced Solid TumorClinical Trials (1)
NCT05585320A Phase 1/2a Study of IMM-1-104 in Participants With Advanced or Metastatic Solid Tumors
Phase 1/2Help build intelligence for Immuneering
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.